Fewer than 40% of new accelerated approvals demonstrate 'high' therapeutic value, study says
As Congress continues to mull whether and how to reform the FDA’s accelerated approval pathway, new research on the pathway continues to crop up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
